This information is without prejudice. Alterations can be made for next year
For diabetes mellitus (DM), one of the most prevalent chronic disease entities, different pathophysiological mechanisms can be identified. Next to the most common form of type II DM (T2DM), type I diabetes (T1DM), gestational diabetes (GDM) and iatrogenic DM, mainly caused by drug-induced disturbances of glucose homeostasis, can be distinguished. Obviously, therapies to combat DM should be tailored to the underlying pathophysiology . Furthermore, hyperglycemia and other phenomena of DM are risk factors to develop (premature) cardiovascular disease.
Prof. dr. J (Koos) Burggraaf (email@example.com)
Adequate knowledge of Pharmacology and (patho-)physiology.
Mode of instruction
Lectures, patient demonstrations, literature reviews and self-study assignments.
Will be announced during the lectures.
In this course, students will learn how to identify key factors in the pathophysiology of diabetes, evaluate currently available compounds related to the underlying pathophysiology, and critically evaluate emerging therapies. To this end, students will learn to assess the value and limitations of animal models and human disease models. In addition to theory, the students will meet patients with diabetes and learn about their difficulty coping with the disease and its sequela. It is expected that the students will develop pharmacology-based ‘solutions’ for the problems that the patients will present to them.
Presentation, verbal examination and report.
Application via uSis. Registration closes 14 days before the start of the course or earlier if the maximum number of students is reached.
A minimum of 5 students and a maximum of 9 students will be admitted. Placement is based on the registration date.
The course will be held at the Centre for Human Drug Research (Zernikedreef 8, Leiden).